JP2017160275A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017160275A5 JP2017160275A5 JP2017124186A JP2017124186A JP2017160275A5 JP 2017160275 A5 JP2017160275 A5 JP 2017160275A5 JP 2017124186 A JP2017124186 A JP 2017124186A JP 2017124186 A JP2017124186 A JP 2017124186A JP 2017160275 A5 JP2017160275 A5 JP 2017160275A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- phenyl
- patient
- methylethyl
- cyclopentyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2,6-bis (1-methylethyl) phenyl Chemical group 0.000 claims 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 8
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 208000014311 Cushing syndrome Diseases 0.000 claims 4
- 230000001919 adrenal effect Effects 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 229960000890 hydrocortisone Drugs 0.000 claims 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 3
- 229960000258 corticotropin Drugs 0.000 claims 3
- 239000003098 androgen Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002395 mineralocorticoid Substances 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- RZRPTBIGEANTGU-UHFFFAOYSA-N -Androst-4-ene-3,11,17-trione Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)=O)C4C3CCC2=C1 RZRPTBIGEANTGU-UHFFFAOYSA-N 0.000 claims 1
- 206010000021 21-hydroxylase deficiency Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical group C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims 1
- BVHCJYWPHHHKRC-UHFFFAOYSA-N Cl.CN(C1=CC=C(C=C1)C1(CCCC1)CNC(=O)N)C Chemical compound Cl.CN(C1=CC=C(C=C1)C1(CCCC1)CNC(=O)N)C BVHCJYWPHHHKRC-UHFFFAOYSA-N 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims 1
- 208000007740 Ectopic ACTH Syndrome Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- RZRPTBIGEANTGU-IRIMSJTPSA-N adrenosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RZRPTBIGEANTGU-IRIMSJTPSA-N 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims 1
- 229960005471 androstenedione Drugs 0.000 claims 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- 208000011590 ectopic ACTH secretion syndrome Diseases 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical group C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims 1
- 229960003248 mifepristone Drugs 0.000 claims 1
- 229960000350 mitotane Drugs 0.000 claims 1
- 229960002847 prasterone Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614269P | 2012-03-22 | 2012-03-22 | |
| US61/614,269 | 2012-03-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501763A Division JP6234987B2 (ja) | 2012-03-22 | 2013-03-13 | 異常な副腎皮質細胞障害を処置するための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017160275A JP2017160275A (ja) | 2017-09-14 |
| JP2017160275A5 true JP2017160275A5 (OSRAM) | 2017-12-21 |
| JP6317016B2 JP6317016B2 (ja) | 2018-04-25 |
Family
ID=48014328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501763A Active JP6234987B2 (ja) | 2012-03-22 | 2013-03-13 | 異常な副腎皮質細胞障害を処置するための化合物および方法 |
| JP2017124186A Active JP6317016B2 (ja) | 2012-03-22 | 2017-06-26 | 異常な副腎皮質細胞障害を処置するための化合物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501763A Active JP6234987B2 (ja) | 2012-03-22 | 2013-03-13 | 異常な副腎皮質細胞障害を処置するための化合物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9107883B2 (OSRAM) |
| EP (1) | EP2838523A1 (OSRAM) |
| JP (2) | JP6234987B2 (OSRAM) |
| CN (2) | CN104302283B (OSRAM) |
| AU (2) | AU2013235535B2 (OSRAM) |
| BR (1) | BR112014023517B1 (OSRAM) |
| CA (1) | CA2867668A1 (OSRAM) |
| HK (1) | HK1206607A1 (OSRAM) |
| IN (1) | IN2014DN08604A (OSRAM) |
| MX (1) | MX355129B (OSRAM) |
| NZ (1) | NZ630828A (OSRAM) |
| WO (1) | WO2013142214A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2748238B2 (ja) | 1994-12-20 | 1998-05-06 | 新興機械工業株式会社 | ばね製造装置の足起こし装置 |
| IN2014DN08604A (OSRAM) * | 2012-03-22 | 2015-05-22 | Univ Michigan | |
| WO2015048543A1 (en) * | 2013-09-26 | 2015-04-02 | Atterocor, Inc. | Treating disorders associated with aberrant adrenocortical cell behavior |
| AU2015320358B2 (en) | 2014-09-26 | 2020-05-14 | Millendo Therapeutics, Inc. | Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto |
| US20160287565A1 (en) * | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| WO2017011302A1 (en) * | 2015-07-10 | 2017-01-19 | Millendo Therapeutics, Inc. | Enhanced bioavailability of n-(2,6-bis(1-methylethyl) phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl) methyl)urea hydrochloride |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| US10780097B2 (en) | 2018-07-02 | 2020-09-22 | Corcept Therapeutics, Inc. | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US10231983B1 (en) | 2018-08-22 | 2019-03-19 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US11202787B2 (en) | 2018-07-02 | 2021-12-21 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US20220241276A1 (en) * | 2019-06-11 | 2022-08-04 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5015644A (en) | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| CN101657471B (zh) * | 2006-12-06 | 2013-07-03 | 史密丝克莱恩比彻姆公司 | 二环化合物及其作为抗糖尿病药的用途 |
| US20090192220A1 (en) * | 2007-11-19 | 2009-07-30 | Ore Pharmaceuticals Inc. | Treatment for solid tumors |
| IN2014DN08604A (OSRAM) * | 2012-03-22 | 2015-05-22 | Univ Michigan |
-
2013
- 2013-03-13 IN IN8604DEN2014 patent/IN2014DN08604A/en unknown
- 2013-03-13 CA CA2867668A patent/CA2867668A1/en not_active Abandoned
- 2013-03-13 EP EP13712998.7A patent/EP2838523A1/en not_active Withdrawn
- 2013-03-13 JP JP2015501763A patent/JP6234987B2/ja active Active
- 2013-03-13 MX MX2014011188A patent/MX355129B/es active IP Right Grant
- 2013-03-13 CN CN201380015269.0A patent/CN104302283B/zh active Active
- 2013-03-13 CN CN201610595176.5A patent/CN106236741A/zh active Pending
- 2013-03-13 BR BR112014023517-1A patent/BR112014023517B1/pt active IP Right Grant
- 2013-03-13 WO PCT/US2013/031068 patent/WO2013142214A1/en not_active Ceased
- 2013-03-13 US US13/802,047 patent/US9107883B2/en active Active
- 2013-03-13 NZ NZ630828A patent/NZ630828A/en unknown
- 2013-03-13 HK HK15107166.6A patent/HK1206607A1/xx unknown
- 2013-03-13 AU AU2013235535A patent/AU2013235535B2/en active Active
-
2015
- 2015-07-13 US US14/798,237 patent/US9446010B2/en active Active
-
2016
- 2016-06-01 US US15/170,682 patent/US9877937B2/en active Active
-
2017
- 2017-06-26 JP JP2017124186A patent/JP6317016B2/ja active Active
- 2017-11-17 AU AU2017261632A patent/AU2017261632A1/en not_active Abandoned
- 2017-12-12 US US15/839,647 patent/US20180256524A1/en not_active Abandoned
-
2021
- 2021-06-30 US US17/364,464 patent/US20220160662A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510933A5 (OSRAM) | ||
| MY147465A (en) | N- (aminoheteroaryl) -1h-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| JP2016513097A5 (OSRAM) | ||
| JP2008510714A5 (OSRAM) | ||
| JP2007513165A5 (OSRAM) | ||
| JP2016535795A5 (OSRAM) | ||
| RU2011108563A (ru) | Способы лечения талассемии | |
| NO20065442L (no) | Amidoforbindelser og deres anvendelse som legemidler | |
| NZ630828A (en) | Compounds and methods for treating aberrant adrenocartical cell disorders | |
| JP2018052983A5 (OSRAM) | ||
| WO2007101224A3 (en) | Inhibitors of the unfolded protein response and methods for their use | |
| JP2012036225A5 (OSRAM) | ||
| JP2012509263A5 (OSRAM) | ||
| JP2012502885A5 (OSRAM) | ||
| JP2017521486A5 (OSRAM) | ||
| WO2009050136A3 (en) | Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome | |
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| JP2020514349A5 (OSRAM) | ||
| CN115803328A (zh) | 哌嗪-2,3-二酮衍生物及其在医药上的应用 | |
| JP2018519324A5 (OSRAM) | ||
| WO2009138186A3 (de) | SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN | |
| JP2019533652A5 (OSRAM) | ||
| JP2016020375A5 (OSRAM) | ||
| JP2017509611A5 (OSRAM) |